Adjuvant therapy: Clinical Trials

289 trials of Adjuvant therapy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

165 completed, 70 unknown, 27 terminated, 16 withdrawn. 141 Phase 2, 99 Phase 3, 38 Phase 1, 16 Not applicable, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2141Completed 80, Unknown 32, Terminated 15, Withdrawn 10, Recruiting 3, Active not recruiting 1
Phase 399Completed 49, Unknown 34, Terminated 8, Withdrawn 3, Active not recruiting 2, Recruiting 2, Suspended 1
Phase 138Completed 28, Terminated 6, Withdrawn 3, Unknown 1
Not applicable16Completed 8, Unknown 5, Active not recruiting 1, Terminated 1, Withdrawn 1
Early Phase 13Completed 3

Follow Adjuvant therapy: new trials by email Literature Review of Adjuvant therapy trials Research Report on Adjuvant therapy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
Observation, Adjuvant therapy - Nasopharyngeal Carcinoma (NPC)
Phase 2RecruitingFudan University1482026-08-012026-08-13
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography - Cutaneous Melanoma
Phase 3RecruitingECOG-ACRIN Cancer Research Group4282026-04-172026-09-24
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
neoadjuvant therapy, Surgery, Adjuvant therapy - NSCLC, Tislelizumab
Phase 2RecruitingQilu Hospital of Shandong University342025-07-252026-10-13
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Adjuvant therapy - Nasopharyngeal Cancinoma (NPC)
Phase 2RecruitingFudan University762024-09-142025-07-16
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Palbociclib, Fulvestrant, Adjuvant Therapy - Breast Cancer
Phase 2Active not recruitingCriterium, Inc.702021-02-092026-10-15
Lymphadenectomy in NSCLC With and Without Adjuvant Therapy
lymphadenectomy - NSCLC, Lymph Node Metastases
UnknownFondazione Policlinico Universitario Agostino Gemelli IRCCS2502020-05-132020-06-09
Predictors of Recurrence for High Risk Endometrial Cancer Patients
adjuvant therapy - High-risk Endometrial Cancer
CompletedFar Eastern Memorial Hospital922020-04-252020-12-09
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Daromun, Surgery, Adjuvant therapy - Melanoma Stage IIIB, Melanoma Stage IIIC
Phase 3RecruitingPhilogen S.p.A.1862018-09-202025-12-17
Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC
Neoadjuvant Chemoradiotherapy, Adjuvant therapy, Surgery - Esophageal Squamous Cell Carcinoma (ESCC)
Phase 3CompletedYongtao Han2542018-01-012025-01-15
POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer
Adjuvant therapy, Axillary treatment - Breast Cancer
Not applicableActive not recruitingUniversity Hospitals of Derby and Burton NHS Foundation Trust19002014-08-012025-07-10
A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma
Chemoradiation Therapy, Adjuvant Therapy - Glioblastoma
Not applicableUnknownShandong Cancer Hospital and Institute202013-08-012016-01-21
Oxaliplatin, Leucovorin, and Fluorouracil Before and After Radiation Therapy and Surgery in Treating Patients With Rectal Cancer That Can Be Removed by Surgery
Leucovorin, fluorouracil, leucovorin calcium - Colorectal Cancer
Phase 2CompletedCardiff University602012-04-012016-09-21
Genetic Susceptibility to Radiation-Induced Skin Reactions in Racial/Ethnic Groups of Patients With Breast Cancer
DNA analysis, gene expression analysis, enzyme-linked immunosorbent assay - Breast Cancer, Cognitive Ability, General
CompletedWake Forest University Health Sciences10002011-09-202023-03-28
Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction
cetuximab, cisplatin, fluorouracil - Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
Phase 2CompletedFederation Francophone de Cancerologie Digestive652011-06-012016-05-30
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor
Not applicableTerminatedGynecologic Oncology Group42011-06-012018-05-22
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
citalopram hydrobromide, escitalopram oxalate, gabapentin - Breast Cancer, Depression
CompletedMayo Clinic882011-03-162025-02-14
Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery
capecitabine, oxaliplatin, active surveillance - Colorectal Cancer
Phase 2 / Phase 3UnknownJeroen Bosch Ziekenhuis15002010-07-012013-08-12
Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide - Brain and Central Nervous System Tumors
Phase 1CompletedCancer Research UK452010-07-012015-10-14
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
cetuximab, cisplatin, docetaxel - Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Phase 3CompletedSwiss Cancer Institute2972010-05-272020-10-20
Radiation Therapy and Ixabepilone in Treating Patients With High-Risk Stage III Prostate Cancer After Surgery
ixabepilone, adjuvant therapy, intensity-modulated radiation therapy - Prostate Cancer
Phase 1 / Phase 2WithdrawnUniversity of Texas Southwestern Medical Center2010-05-262020-08-20

Showing 20 of 289. Sign in to see all of them.

Conditions studied

Breast Neoplasms (64)  ·  Central Nervous System Neoplasms (37)  ·  Colorectal Neoplasms (31)  ·  Colonic Neoplasms (25)  ·  Rectal Neoplasms (23)  ·  Glioblastoma (21)  ·  Gliosarcoma (19)  ·  Carcinoma, Non-Small-Cell Lung (17)  ·  Lung Neoplasms (17)  ·  Head and Neck Neoplasms (15)  ·  Sarcoma (14)  ·  Squamous Cell Carcinoma of Head and Neck (13)  ·  Melanoma (12)  ·  Prostatic Neoplasms (12)  ·  Astrocytoma (11)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (22)  ·  Children's Cancer and Leukaemia Group (12)  ·  National Cancer Institute (NCI) (11)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (11)  ·  Memorial Sloan Kettering Cancer Center (10)  ·  Case Comprehensive Cancer Center (9)  ·  Mayo Clinic (8)  ·  UNICANCER (8)  ·  Institute of Cancer Research, United Kingdom (7)  ·  Children's Oncology Group (6)  ·  City of Hope Medical Center (6)  ·  Radiation Therapy Oncology Group (6)  ·  Roswell Park Cancer Institute (6)  ·  Gynecologic Oncology Group (4)  ·  Medical Research Council (4)

Countries

United States (129)  ·  United Kingdom (65)  ·  France (36)  ·  Italy (28)  ·  Netherlands (28)  ·  Belgium (25)  ·  Germany (24)  ·  Switzerland (22)  ·  Canada (19)  ·  Spain (17)  ·  Australia (14)  ·  Ireland (13)  ·  Austria (11)  ·  Portugal (10)  ·  Sweden (9)

Top investigators

Edward F. McClay, MD (3)  ·  Larry Kleinberg, MD (3)  ·  Laurent Bedenne, MD (3)  ·  Vered Stearns, MD (3)  ·  William W. Wong, MD (3)  ·  Aaron H. Wolfson, MD (2)  ·  Alexander M. M. Eggermont, MD, PhD (2)  ·  Ann Barrett (2)  ·  Barbara L. Smith, MD, PhD (2)  ·  Barry Pizer, MD (2)  ·  Bernard Nordlinger, MD (2)  ·  Daniel Rea, MD (2)  ·  David Cunningham, MD (2)  ·  David Ellison, MD (2)  ·  David J. Adelstein, MD (2)

Results publications

PMID 25592642, PMID 10394416, PMID 11286848, PMID 11835236, PMID 12573762, PMID 12749710, PMID 12957458, PMID 15667958, PMID 15821648, PMID 16399443, PMID 16524973, PMID 16868545, PMID 17013570, PMID 17030548, PMID 17240136, PMID 17401004, PMID 17607120, PMID 17652651, PMID 17698804, PMID 17705175, PMID 17822748, PMID 17878480, PMID 17971585, PMID 18083404, PMID 18191528, PMID 18358928, PMID 18372134, PMID 18403492, PMID 18509084, PMID 18620949, PMID 18797468, PMID 18952561, PMID 19070889, PMID 19218306, PMID 19231157, PMID 19269519, PMID 19269520, PMID 19273696, PMID 19364653, PMID 19430405, PMID 19433686, PMID 19554377, PMID 19621225, PMID 19682889, PMID 19793643, PMID 19816190, PMID 19893425, PMID 19945857, PMID 20063546, PMID 20100142

NIH funding

P30CA006973 (9), P30CA043703 (8), P30CA015083 (7), P30CA033572 (6), U10CA032102 (4), 2005 (3), U01CA062475 (3), 2004 (2), P30CA008748 (2), P30CA036727 (2), U10CA027469 (2), 2008 (1), 2009 (1), 2023 (1), P30CA006516 (1)